Efficacy and safety of the single-dose pegylated G-CSF vs. daily G-CSF for peripheral blood stem cells mobilization in donors: a multicenter, randomized controlled trial - Takeaways - MDSpire

Efficacy and safety of the single-dose pegylated G-CSF vs. daily G-CSF for peripheral blood stem cells mobilization in donors: a multicenter, randomized controlled trial

  • By

  • Jiali Li

  • Sha Zhou

  • Xiaoping Li

  • Xiangyu Ma

  • Sanbin Wang

  • Yicheng Zhang

  • Shifeng Lou

  • Jun Rao

  • Ping Wang

  • Lidan Zhu

  • Ting Chen

  • Xixi Xiang

  • Shichun Gao

  • Han Yao

  • Peiyan Kong

  • Lei Gao

  • Cheng Zhang

  • Xi Zhang

  • Li Gao

  • June 24, 2026

  • 0 min

Share

  • 1

    This study compares the efficacy and safety of single-dose Peg-G-CSF versus daily G-CSF for mobilizing peripheral blood stem cells in healthy donors.

  • 2

    Eighty-three percent of donors receiving Peg-G-CSF collected sufficient CD34+ cells, comparable to 79% in the G-CSF group after apheresis.

  • 3

    The peak circulating CD34+ cell count occurred on day 5 for both Peg-G-CSF and G-CSF groups, indicating similar mobilization timing.

  • 4

    No significant differences were found in side effects, engraftment, GVHD, or survival rates between recipients of stem cells from both donor groups.

  • 5

    The study suggests that Peg-G-CSF may provide a more convenient alternative to traditional G-CSF for stem cell mobilization.

Original Source(s)

Efficacy and safety of the single-dose pegylated G-CSF vs. daily G-CSF for peripheral blood stem cells mobilization in donors: a multicenter, randomized controlled trial

  • by Jiali Li, Sha Zhou, Xiaoping Li, Xiangyu Ma, Sanbin Wang, Yicheng Zhang, Shifeng Lou, Jun Rao, Ping Wang, Lidan Zhu, Ting Chen, Xixi Xiang, Shichun Gao, Han Yao, Peiyan Kong, Lei Gao, Cheng Zhang, Xi Zhang, Li Gao

  • June 24, 2026

Related Content

Radioimmunotherapy as a targeted strategy of reduced-intensity conditioning for allogeneic transplantation in leukemia

Long-term trends in the burden of leukemia subtypes in China from 1990 to 2021: a Joinpoint regression and age-period-cohort analysis based on GBD 2021

Roswell Park is Hiring!

Working at Roswell Park will afford you incredible opportunities to work alongside some of the nation’s foremost clinicians and researchers to broaden your career experiences and be part of a team that eases the burden of cancer.

  • May 19, 2025

  • 1 min